PEPTIDES BUSINESS WIRE
Questions and queries
If we know one thing about peptides it’s how little Americans know, with both doctors and patients swimming against a flood of misinformation and struggling to make sense of how even the most basic information applies to their health or their practice.
TruthTides is trying to change that, developing peptide education courses to meet a central challenge for prescribing clinicians: understanding what the science supports, where the evidence falls short, and how to apply that understanding in practice. Part of the company’s effort to bring clarity and widen the audience for that clarity is an AI model on the Truth-Tides.com site carefully confined to established science. Both licensed clinicians and consumers can post questions to TruthTide’s AI and receive answers more dependable than what they might get from an influencer or a trending TikTok video.
What makes that interesting to Peptides Business Wire is what the questions they ask tell us about the level of sophistication and the varying interests across the consumer and clinician communities. So far, it indicates that many people on both sides of the patient/practitioner divide are cautiously tiptoeing their way into the peptide space.
We asked TruthTides for the top five questions asked by both groups to take stock of that mix of curiosity and caution.
Let’s dive in
PEPTIDES INDUSTRY SIGNAL
🌎 Here is the scoop:
Clinicians
BPC-157 for tendon/joint healing is a question for more clinicians than any other subject. Doctors are specifically asking about "BPC 157 and supraspinatus swelling" and "peptides for joint arthritis." While BPC-157 is likely the most commonly known peptide outside of GLP-1s, making it an obvious subject of inquiry, the direct connection to joint issues and arthritis suggests that doctors are seeing older patients than many observers of the emerging peptide therapy field may have assumed.
Doctors are highly interested in dosing and protocols, indicating that existing training programs have yet to penetrate the clinician community to meet the need for information. Doctors are asking about "pinealon dosing for cognition vs sleep," and tesamorelin/ipamorelin blends.
Questions about cognitive and neurological health compounds, including semax and cerebrolysin for early Parkinson's, is a sign that doctors are frustrated with established treatments and models of care. Doctors specifically asking for human evidence for epitalon treatment suggests many of them are treading carefully.
The number of questions about single compounds may indicate that doctors are finding information from other sources. It may also be that patients are bringing questions into the office that clinicians are finding it challenging to answer. Peptides and compounds drawing interest include GHK-Cu, NAD+, Tirzepatide, ARA-290, and Thymosin Alpha-1.
An urgent demand for reliable sourcing is obvious in how often the phrase "where to get it" shows up in questions.
Patients —
1. As with clinicians, BPC-157 is the top topic of interest. Curiosity about the “what does it do?” dominates patient curiosity, meaning many consumers bring more curiosity than experience to the peptide market.
2. A level of reluctance or at least caution is made clear by questions related to “Is this safe? What should I know?” Concerns about safety and side effects go past the lesser-known peptides to include GLP-1s.
3. A large number of questions focus on the potential for peptides to treat gut health issues. TruthTides labels gut health a “consistent second-tier interest.”
4. The shallow depth of knowledge of peptides is proven by questions in the "What should I take?" theme. The inquiries can get as specific as "What should I use as a 26 yr old male," and also delve into dosing. This could be a warning sign for practitioners that many patients are taking peptide therapy into their own hands.
5. It may be surprising that questions about weight-loss peptides, including Tirzepatide, Retatrutide, and Semaglutide, did not outnumber the previous questions in this list. A possible takeaway here is that people are already looking past the blockbuster GLP-1s to consider other conditions and need states. It may also be that many consumers don’t consider the drugs to be “peptides,” or at least consider them a different class.
ENFORCEMENT UPDATE
September 1-8, 2026 (sponsored by Boesen & Snow Law)
FDA fires off warning letters to five peptide sellers
The FDA sent warning letters dated August 24 to five companies accused of illegally marketing unapproved peptide drugs, including semaglutide, tirzepatide, retatrutide, and other compounds pitched for weight loss and anti-aging. The letters, posted to the agency's site September 1, name individual owners and managers behind each operation. Companies have 15 business days to respond, a deadline that lands squarely in this window.
NuScience Peptides LLC (Cornelius, NC), managed by Joseph and Ratsamy DeRosa
Peak Performance Peptides (Phoenix, AZ), founded by Jeffrey Deng
Peptide Partners LLC (Sarasota, FL), tied to Zachary David Hoff
Tex Peptides / TXP Innovations LLC (Dallas, TX), led by CEO Felicia Romero
Royal Peptides LLC (Boynton Beach, FL), managed by Rocco Abate and Michael Fraunfelter
(No charges have been filed. Warning letters are allegations, not findings of guilt.)
Prison time for peptide vendor. Matthew Kawa of Grant Park, IL, owner of Paradigm Peptides, was sentenced August 1 to nearly six years in federal prison for selling steroid-adulterated peptides to roughly 54,000 customers nationwide. A co-defendant, Jennifer Stechkober, received 16 months. The judge called it "an incredible trail of harm."
Med spa murder charges. Amber Johnson, owner of Luxe Med Spa in Wortham, TX, and Dr. Michael Gallagher, the spa's medical director, face murder and related charges in the 2023 IV-infusion death of a 47-year-old patient. Johnson was not licensed to practice medicine.
Utah doctor indicted. Osteopathic physician Justin Watkins of Pleasant View, UT, was indicted this spring for allegedly selling misbranded peptides imported from China to more than 200 patients through his clinic, TruHealth.
Two states tell doctors: stop prescribing "research-grade" peptides. Medical and pharmacy boards in Mississippi and South Carolina issued statements this summer barring licensees from compounding, dispensing, or recommending non-FDA-approved peptides to patients. Alabama issued similar guidance in May.
Compiled from FDA, DOJ, and state licensing board records. Warning letters and indictments reflect allegations pending response or adjudication.
The number of questions about single compounds may indicate that doctors are finding information from other sources. It may also be that patients are bringing questions into the office that clinicians are finding it challenging to answer.
Until next week,
Peptides Business Wire